CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Sees Large Decrease in Short Interest

CollPlant Biotechnologies Ltd. (NASDAQ:CLGNGet Free Report) saw a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 4,800 shares, a decrease of 25.0% from the February 13th total of 6,400 shares. Based on an average daily volume of 8,600 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.1% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of CollPlant Biotechnologies in a research report on Friday, November 29th. D. Boral Capital restated a “buy” rating and set a $14.00 price objective on shares of CollPlant Biotechnologies in a report on Wednesday, February 12th.

View Our Latest Report on CollPlant Biotechnologies

Institutional Trading of CollPlant Biotechnologies

Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC purchased a new position in CollPlant Biotechnologies during the 4th quarter worth $38,000. Wells Fargo & Company MN grew its position in shares of CollPlant Biotechnologies by 110.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock worth $30,000 after buying an additional 4,405 shares in the last quarter. AMH Equity Ltd increased its stake in shares of CollPlant Biotechnologies by 17.4% during the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after buying an additional 17,295 shares during the period. Finally, Benjamin Edwards Inc. bought a new stake in shares of CollPlant Biotechnologies in the third quarter valued at about $112,000. Institutional investors own 21.69% of the company’s stock.

CollPlant Biotechnologies Price Performance

Shares of CLGN opened at $3.30 on Tuesday. The firm has a market capitalization of $37.76 million, a price-to-earnings ratio of -2.14 and a beta of 1.07. The company has a 50-day moving average of $3.66 and a 200 day moving average of $4.06. CollPlant Biotechnologies has a 1-year low of $3.00 and a 1-year high of $6.75.

CollPlant Biotechnologies Company Profile

(Get Free Report)

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.

Featured Stories

Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.